Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$10.43 USD

10.43
1,551,340

+0.15 (1.46%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $10.43 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Momentum in Dynavax Technologies (DVAX) Should Keep going

by Zacks Equity Research

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering

by Zacks Equity Research

Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.

AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study

by Zacks Equity Research

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.

Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study

by Zacks Equity Research

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.

Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals

by Zacks Equity Research

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.

Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update

by Zacks Equity Research

Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.

Roche's (RHHBY) Vabysmo Positive in Late-Stage RVO Studies

by Zacks Equity Research

Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase III studies for retinal vein occlusion.

uniQure (QURE) Up on Restructuring Plans, Workforce Reduction

by Zacks Equity Research

uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook

by Zacks Equity Research

Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.

Viatris (VTRS) to Divest Some More Businesses, Shares Gain

by Zacks Equity Research

Viatris (VTRS) enters into agreements to divest its remaining businesses previously planned for 2023. Its shareholders are upbeat about the same.

Novartis (NVS) Announces Positive Data on Kidney Disease Drug

by Zacks Equity Research

Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.

PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024

by Zacks Equity Research

PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination request for the negative CHMP opinion on Translarna.

Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 73.92%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 73.9% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%

by Zacks Equity Research

Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%.

Here's What Could Help Dynavax Technologies (DVAX) Maintain Its Recent Price Strength

by Zacks Equity Research

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why

by Zacks Equity Research

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

by Zacks Equity Research

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.

Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study

by Zacks Equity Research

Pliant's (PLRX) phase II study on lead pipeline candidate bexotegrast, achieves its primary and secondary endpoints. Shares rise

Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data

by Zacks Equity Research

Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.

Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down

by Zacks Equity Research

Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.

Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs

by Zacks Equity Research

Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.

Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study

by Zacks Equity Research

Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.

AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study

by Zacks Equity Research

AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.

Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study

by Zacks Equity Research

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.

Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study

by Zacks Equity Research

Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.